ReviewCancers2022

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival.

Tao Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.